Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients
Status:
Recruiting
Trial end date:
2025-06-10
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the safety, pharmacokinetics and preliminary
efficacy of combinations treatment of ruxolitinib with 5 novel compounds: siremadlin,
crizanlizumab, sabatolimab, LTT462 and NIS793 in myelofibrosis (MF) subjects.